Approaches in the Frontline Treatment of EGFR-Positive NSCLC
Edward B. Garon, MD, MS, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses current approaches for the first-line treatment of patients with EGFR-positive NSCLC.
Transcript:
Dr. Edward Garon: Hello, I'm Edward Garon from the Jonsson Comprehensive Cancer Center at UCLA. I'm excited to have had the opportunity to give these talks at the meeting here in Long Beach, local for me this year.
The first talk that I gave was on the subject of front-line approaches for EGFR mutation-positive non-small cell lung cancer. I really focused on the sensitizing and traditional sensitizing mutations of EGFR exon 19 deletion as well as the L858R mutation.
Of course, this is an exciting area in that it's really only been about 10 years since we knew that the EGFR mutation predicted for response with the EGFR inhibitors. We have seen a lot of development in this area.
Overall, really at least in the United States, the established front-line therapy at this point has been osimertinib. The data that was recently updated earlier this year really indicated that there was also a survival advantage for osimertinib over first-line EGFR TKI that would be of a first generation, either orantinib or gefitinib.
That being said, there are a few approaches particularly combinations of EGFR inhibitors and antiangiogenics as well as EGFR inhibitors plus chemotherapy, that I would argue are certainly of interest, have shown really progression-free survival data that is similar to what has been seen with osimertinib, and also does have the potential for having patients subsequently respond to osimertinib when they develop T790M mutation in particular.
It is an exciting area which currently has an established leader, being single-agent osimertinib, but that there are other approaches on the horizon that are of some interest certainly.
